{
  "ResponseCode": 200,
  "Message": "Success",
  "data": [
    {
      "phase": "III",
      "approval_date": "20190919",
      "is_active": 1,
      "qcStatus": "QC1",
      "SourceFileName": "Protocol Amendment (Study Level) - 02 - Administrative Letters 01 and 02 - 19-Sep-2019.pdf",
      "Indication": "Hepatocellular carcinoma",
      "ProjectId": "",
      "ProtocolNo": "CA2099DX",
      "documentPath": "\\\\quintiles.net\\enterprise\\Services\\protdigtest\\pilot_iqvxml\\cc17c63a-a17d-4cd7-ae78-c5c89fc45dd2",
      "VersionNumber": "2",
      "ProtocolTitle": "A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation",
      "DocumentStatus": "final",
      "SponsorName": "ONO",
      "uploadDate": "20210730204516",
      "AiDocId": "cc17c63a-a17d-4cd7-ae78-c5c89fc45dd2",
      "MoleculeDevice": "Nivolumab",
      "Follow": false,
      "UserRole": "secondary"
    }
  ],
  "count": 1,
  "pageNo": 1,
  "sortField": "score",
  "total_count": 1,
  "phases": [
    "",
    "II",
    "III",
    "Ia/Ib",
    "Ib/II"
  ],
  "indications": [
    "ABCC6 deficiency",
    "Abdominal aortic aneurysm",
    "Abnormal male sexual function",
    "Acute lymphocytic leukemia",
    "Allergic rhinitis",
    "Hepatocellular Carcinoma",
    "Hepatocellular carcinoma",
    "LOCALLY ADVANCED OR METASTATIC SOLID TUMORS",
    "Non-small cell lung cancer",
    "Unresectable HCC",
    "aa",
    "ind",
    "sa"
  ],
  "sponsors": [
    "(CKD)Chong Kun Dang Pharm",
    "3-D Pharmaceuticals",
    "3D Medical",
    "3M Healthcare",
    "7TM Pharma",
    "BEIGENE",
    "Chugai Pharmaceutical Co Ltd",
    "HENGRUI",
    "ONO",
    "XIAN_XINTONG",
    "Xian Xintong Pharmaceutical Research Co Ltd",
    "Yiviva Inc",
    "s1"
  ]
}